Cannabis Science has Taken a Leadership Role to Progress its Pharmaceutical Products Under the New Policies the Federal Government has Implemented for the Use of Medical Cannabis

July 27, 2010

COLORADO SPRINGS, Colo., (GLOBE NEWSWIRE) -- Cannabis Science, Inc. (OTCBB:CBIS - News), a pioneering US biotech company developing pharmaceutical cannabis products, has hailed the new Veterans Affairs position allowing medical use of marijuana by Vets in states with medical marijuana laws as validating the company's strategy.

Cannabis Science President and CEO, Dr. Robert Melamede, PhD, states, "We believe it is inappropriate that our veterans have access to cannabis based medicines in some states while others are denied their medicines because their states have not yet approved medical marijuana. Cannabis Science will remedy this situation by taking our cannabis-based products through the FDA process for nationwide distribution. This way all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. We believe that the new Federal policies are not only a validation of our decision to focus on helping disabled vets, but also an implicit recognition of the need to reschedule cannabis so that cannabis medicines will have a wider medical availability. After all, cannabis medicines are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year. There is no effective lethal dose for cannabis. "

Richard Cowan, Cannabis Science CFO, added, "We continue to work on developing cannabis extracts for FDA approval, but we are also developing the Cannabis Science brand for products that can be sold in states with medical marijuana laws, and in pharmacies when the Federal government recognizes that its current scheduling of cannabis is scientifically absurd. We think rescheduling is now inevitable. The only question is 'when'."

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact
Cannabis Science Inc.
Mark J. Friedman, Investor Relations
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com
1.877.431.CBIS (2247)
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
www.cannabisscience.com